Q3 2024 Presentation and Q&A

Fri, 8 Nov, 2024, 13:00 – 14:00

This event has ended. Sign up below to watch the recording.

How does this Q&A work:

This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.

The company will address as many questions as possible, and focus on those questions most wanted by investors.

Speakers at this event:

Jakob Knudsen

CEO

Josephine Baum Jørgensen

CFO

3 Questions

Peter markmann
Nov. 7, 2024

Who do you see as customers for the new released finger print test - SuPAR nostic POC - and market potential?

Who is behind the new US company “SuPAR Health”.
Do “they” have any knowledge/relations of the Healt/ longevity market.
What is long term sales potential in US - both for Sobi and SuPAR Health?

Upvote

2 upvotes

Answered by Jakob Knudsen - CEO at Virogates , Jakob Knudsen - CEO at Virogates , Jakob Knudsen - CEO at Virogates

See answer

A**** *****
Nov. 7, 2024

Cna you put some more words around the new suPAR Health LLC agreement and what kind of volumes there can be expected from this?

Upvote

1 upvote

Answered by Jakob Knudsen - CEO at Virogates

See answer

S**** *****
Nov. 8, 2024

Do you have an estimation of revenue effect in 2025 from the SOBI collaboration?

Upvote

0 upvotes

Answered by Josephine Baum Jørgensen - CFO at Virogates

See answer